Founded in 2000, IRAZÚ Biodiscovery, LLC (IB) is focused on discovering and developing nutraceuticals and pharmaceuticals that mimic the age-decelerating effects of caloric restriction (CR). Based on its patent-pending discovery of the mechanism involved in CR protection, IB is developing preventive as well as therapeutic interventions aimed at delaying the onset of pathologies normally associated with aging, slowing the aging process, lowering disability rates, and maintaining a vital and healthier life span.

The past century has seen an unprecedented increase in the average human being’s life span, from 47 years in 1900 to 76 years in 1997, and it is projected that by 2030, older Americans will constitute 20% of the population.

With increased longevity, however, comes greater risk of suffering from chronic age-related diseases and conditions such as cancer, stroke, arthritis, heart disease, Alzheimer’s, osteoporosis, depression, and diabetes.  Although, the human cost of these illnesses on tens of millions of patients and their families is not quantifiable, the Alliance for Aging Research calculates that even a brief delay in the aggregate onset of age-related disability can translate into dramatic savings for the U.S. economy.

Caloric restriction (CR)—generally defined as the practice of undernutrition without malnutrition — is widely recognized as the only paradigm that has been demonstrated through extensive experimentation not only to extend life span in a variety of species, but to decelerate the onset of age-associated diseases. CR has been shown in repeated experiments to extend mean and maximum life span, decelerate the rate of aging, and inhibit the onset of a number of life-shortening diseases in laboratory animals.

An understanding of the biological mechanism involved in CR protection will provide the means of retarding chronic disease and extending maximum life span in humans.  After 65 years of extensive study, however, revealing this mechanism has proven elusive, in part because researchers have been searching for the mechanism through studies designed to elucidate the process of aging itself.

Irazú applied an entirely novel approach that involved searching for an upstream metabolic trigger—a biochemical “switch”—that would turn on events at the molecular, cellular, tissue, and organ levels to induce CR-protective benefits. This biochemical trigger mechanism is precisely what IRAZÚ has discovered.

Successful implementation of Irazú’s novel technology would change conventional views on disease prevention and dramatically affect the quality of life in old age. It is also clear that the economic impact on health care and the commercial value of Irazu’s technology would be substantial, with potential applications in geriatric medicine, preventive medicine, sports medicine, surgery, and national defense.

For more information, contact:

Marco A. Chacón, Ph.D., Managing Member

(410) 975-4050 Phone

(410) 605-2028 Fax

or  email Irazu using the below form.

801 West Baltimore Street, Suite 401, Baltimore, MD 21201